Form 4: Sutro Biopharma Director Connie Matsui Acquires 35,000 Stock Options
SEC Form 4 Filing
Director Connie Matsui acquired 35,000 stock options in Sutro Biopharma, Inc. on June 6, 2024.
Summary
- On June 6, 2024, Connie Matsui, a director of Sutro Biopharma, Inc., acquired 35,000 stock options.
- The options have an exercise price of $3.76.
- The options vest monthly starting July 6, 2024, with full vesting by the earlier of the 2025 annual stockholders meeting or June 6, 2025.
- The options expire on June 6, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral as it reports a standard transaction. The acquisition of options by a director can be seen as a slightly positive sign, but it's a routine event.
Positives
- The acquisition of stock options by a director signals confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be informative for investors.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/06/2024 | Date of transaction: Connie Matsui acquired 35,000 stock options. |
| 07/06/2024 | Vesting of the options commences. |
| 06/06/2025 | Options are fully vested by this date, or the date of the 2025 annual stockholders meeting, whichever is earlier. |
| 06/06/2034 | Expiration date of the stock options. |
| 06/10/2024 | Date of filing of the Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.